Revolutionary CancerVax Appoints Top Expert to Lead Breakthrough Cancer Treatment Initiative

Lehi, Utah – November 19, 2024 – In a game-changing move for cancer treatment, CancerVax, Inc. proudly announces the appointment of Dr. George Katibah as the new Chief Scientific Officer. This strategic hire positions CancerVax at the forefront of immunotherapy innovation, promising to leverage the body's immune system in a groundbreaking universal cancer treatment platform.

Byron Elton, the CEO of CancerVax, expressed his enthusiasm about Dr. Katibah's leadership: “We are thrilled to welcome Dr. Katibah, who has proven invaluable during his time as an advisor. His extensive expertise in oncology and immunology will be instrumental as we advance our novel cancer treatment technologies. His immediate focus will be to propel our preclinical development forward, paving the way for crucial animal studies and beyond.”

Dr. Katibah comes with an impressive background, having previously served as Director of Discovery Biology at RAPT Therapeutics and Head of Biochemistry at Aduro Biotech. He earned his PhD in Molecular and Cell Biology from the prestigious University of California, Berkeley. His research background uniquely positions him to lead CancerVax into a new era of innovative cancer therapies.

“I’m excited to be joining CancerVax and taking on the role of Chief Scientific Officer,” remarked Dr. Katibah. “Our proprietary approach to treating cancer is unprecedented. We aim to accurately detect cancer cells, instruct them to express common pathogen proteins, and efficiently activate the immune response to eliminate these cells. This strategy combines well-researched individual steps in a novel way that has the potential to revolutionize cancer treatment.”

In addition to this appointment, CancerVax has recently relocated its headquarters to Lehi, Utah. This area has become a thriving hub for tech companies and biotech startups, fostering a dynamic community teeming with talent and investment opportunities.

CancerVax is committed to advancing its Universal Cancer Treatment platform, which will function as a customizable injection aimed at targeting various forms of cancer. The innovative approach DETECTS, MARKS, and KILLS cancer cells by tricking the immune system into recognizing them as common diseases like measles or chickenpox. Additionally, the company has made strides in developing a specific immunotherapy targeting Ewing sarcoma, a rare but aggressive cancer primarily affecting younger populations.

The vision is clear—CancerVax aims to make cancer treatment as simple as getting a shot, revolutionizing the landscape of oncology.

As we look ahead, the excitement surrounding CancerVax's advancements is palpable. With Dr. Katibah leading the charge and the company's innovative research methods, the future of cancer treatment looks promising. Stay tuned for groundbreaking discoveries that may redefine how we combat this devastating disease.